Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892050 | 0.85 | CNR1 (0.47) | CNR1BRAFEGFRKDRTGFBR1 | |
| SCHEMBL3142551 | 0.82 | KDR (0.41) | BRAFKDRMEN1NPC1RAB9A | |
| SCHEMBL3143142 | 0.78 | SLC2A1 (0.61) | PDE10ASLC2A1KDRMEN1NPC1 | |
| SCHEMBL3142884 | 0.75 | BTK (0.51) | CNR1KDRTGFBR1KDM4EBTK | |
| SCHEMBL6658632 | 0.74 | CDK2 (0.54) | SLC2A1KDRMEN1NPC1RAB9A | |
| SCHEMBL4898748 | 0.73 | SLC2A1 (0.50) | PDE10ASLC2A1EGFRTNNI3KKDR | |
| SCHEMBL4901584 | 0.73 | SLC2A1 (0.48) | PDE10ASLC2A1EGFRTNNI3KKDR | |
| SCHEMBL4892301 | 0.72 | SLC2A1 (0.44) | SLC2A1EGFRTNNI3KKDRMEN1 | |
| Hydrochloric Acid SCHEMBL4896691 | 0.72 | SLC2A1 (0.47) | PDE10ASLC2A1EGFRTNNI3KKDR | |
| Hydrochloric Acid SCHEMBL4891120 | 0.69 | SLC2A1 (0.62) | PDE10ASLC2A1KDRMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | PDE10A 2762/4885SLC2A1 1451/4885CNR1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.